

# World Journal of *Gastroenterology*

*World J Gastroenterol* 2023 February 28; 29(8): 1243-1394



## Contents

Weekly Volume 29 Number 8 February 28, 2023

## REVIEW

- 1243 Predictors of early and late hepatocellular carcinoma recurrence  
*Nevola R, Ruocco R, Criscuolo L, Villani A, Alfano M, Beccia D, Imbriani S, Claar E, Cozzolino D, Sasso FC, Marrone A, Adinolfi LE, Rinaldi L*
- 1261 Functional constipation in children: What physicians should know  
*Tran DL, Sintusek P*
- 1289 Early-onset colorectal cancer: A review of current knowledge  
*Saraiva MR, Rosa I, Claro I*

## MINIREVIEWS

- 1304 Hamartomatous polyps: Diagnosis, surveillance, and management  
*Gorji L, Albrecht P*

## ORIGINAL ARTICLE

## Basic Study

- 1315 Stress granules inhibit endoplasmic reticulum stress-mediated apoptosis during hypoxia-induced injury in acute liver failure  
*Li WY, Yang F, Li X, Wang LW, Wang Y*

## Observational Study

- 1330 Intestinal complications in Brazilian patients with ulcerative colitis treated with conventional therapy between 2011 and 2020  
*Martins AL, Galhardi Gasparini R, Sasaki LY, Saad-Hossne R, Ritter AMV, Barreto TB, Marcolino T, Yang Santos C*
- 1344 Establishment of a prediction model for severe acute radiation enteritis associated with cervical cancer radiotherapy  
*Ma CY, Zhao J, Gan GH, He XL, Xu XT, Qin SB, Wang LL, Li L, Zhou JY*
- 1359 Better performance of PIVKA-II for detecting hepatocellular carcinoma in patients with chronic liver disease with normal total bilirubin  
*Qian XJ, Wen ZM, Huang XM, Feng HJ, Lin SS, Liu YN, Li SC, Zhang Y, Peng WG, Yang JR, Zheng ZY, Zhang L, Zhang DW, Lu FM, Liu LJ, Pan WD*

## SYSTEMATIC REVIEWS

- 1374 Burden of bone disease in chronic pancreatitis: A systematic review and meta-analysis  
*Chhoda A, Hernandez-Woodbine MJ, Addo NAA, Nasir SA, Grimshaw A, Gunderson C, Ahmed A, Freedman SD, Sheth SG*

**ABOUT COVER**

Editorial Board Member of *World Journal of Gastroenterology*, Ragesh Babu Thandassery, MD, Assistant Professor, Doctor, Department of Medicine, Central Arkansas Veterans Healthcare System, Little Rock, AR 72205, United States. doc.ragesh@gmail.com

**AIMS AND SCOPE**

The primary aim of *World Journal of Gastroenterology* (WJG, *World J Gastroenterol*) is to provide scholars and readers from various fields of gastroenterology and hepatology with a platform to publish high-quality basic and clinical research articles and communicate their research findings online. WJG mainly publishes articles reporting research results and findings obtained in the field of gastroenterology and hepatology and covering a wide range of topics including gastroenterology, hepatology, gastrointestinal endoscopy, gastrointestinal surgery, gastrointestinal oncology, and pediatric gastroenterology.

**INDEXING/ABSTRACTING**

The WJG is now abstracted and indexed in Science Citation Index Expanded (SCIE, also known as SciSearch®), Current Contents/Clinical Medicine, Journal Citation Reports, Index Medicus, MEDLINE, PubMed, PubMed Central, Scopus, Reference Citation Analysis, China National Knowledge Infrastructure, China Science and Technology Journal Database, and Superstar Journals Database. The 2022 edition of Journal Citation Reports® cites the 2021 impact factor (IF) for WJG as 5.374; IF without journal self cites: 5.187; 5-year IF: 5.715; Journal Citation Indicator: 0.84; Ranking: 31 among 93 journals in gastroenterology and hepatology; and Quartile category: Q2. The WJG's CiteScore for 2021 is 8.1 and Scopus CiteScore rank 2021: Gastroenterology is 18/149.

**RESPONSIBLE EDITORS FOR THIS ISSUE**

Production Editor: *Yu-Xi Chen*; Production Department Director: *Xu Guo*; Editorial Office Director: *Jia-Ru Fan*.

**NAME OF JOURNAL**

*World Journal of Gastroenterology*

**ISSN**

ISSN 1007-9327 (print) ISSN 2219-2840 (online)

**LAUNCH DATE**

October 1, 1995

**FREQUENCY**

Weekly

**EDITORS-IN-CHIEF**

Andrzej S Tarnawski

**EDITORIAL BOARD MEMBERS**

<http://www.wjgnet.com/1007-9327/editorialboard.htm>

**PUBLICATION DATE**

February 28, 2023

**COPYRIGHT**

© 2023 Baishideng Publishing Group Inc

**INSTRUCTIONS TO AUTHORS**

<https://www.wjgnet.com/bpg/gerinfo/204>

**GUIDELINES FOR ETHICS DOCUMENTS**

<https://www.wjgnet.com/bpg/GerInfo/287>

**GUIDELINES FOR NON-NATIVE SPEAKERS OF ENGLISH**

<https://www.wjgnet.com/bpg/gerinfo/240>

**PUBLICATION ETHICS**

<https://www.wjgnet.com/bpg/GerInfo/288>

**PUBLICATION MISCONDUCT**

<https://www.wjgnet.com/bpg/gerinfo/208>

**ARTICLE PROCESSING CHARGE**

<https://www.wjgnet.com/bpg/gerinfo/242>

**STEPS FOR SUBMITTING MANUSCRIPTS**

<https://www.wjgnet.com/bpg/GerInfo/239>

**ONLINE SUBMISSION**

<https://www.f6publishing.com>



## Hamartomatous polyps: Diagnosis, surveillance, and management

Leva Gorji, Peter Albrecht

**Specialty type:** Gastroenterology and hepatology

**Provenance and peer review:** Invited article; Externally peer reviewed.

**Peer-review model:** Single blind

**Peer-review report's scientific quality classification**

Grade A (Excellent): 0  
Grade B (Very good): B, B  
Grade C (Good): C  
Grade D (Fair): 0  
Grade E (Poor): 0

**P-Reviewer:** Barone M, Italy; Shekouhi R, Iran; Yamamura T, Japan

**Received:** September 13, 2022

**Peer-review started:** September 13, 2022

**First decision:** December 1, 2022

**Revised:** December 8, 2022

**Accepted:** February 16, 2023

**Article in press:** February 16, 2023

**Published online:** February 28, 2023



**Leva Gorji, Peter Albrecht**, Department of Surgery, Kettering Health Dayton, Dayton, OH 45405, United States

**Corresponding author:** Leva Gorji, DO, Doctor, Department of Surgery, Kettering Health Dayton, 405 West Grand Avenue Dayton, Dayton, OH 45405, United States.  
[leva.gorji@ketteringhealth.org](mailto:leva.gorji@ketteringhealth.org)

### Abstract

Hereditary polyposis syndrome can be divided into three categories: Adenomatous, serrated, and hamartomatous polyps. Hamartomatous polyps, malformations of normal tissue presenting in a disorganized manner, are characterized by an autosomal dominant inheritance pattern. These syndromes exhibit hamartomatous gastrointestinal polyps in conjunction to extra-intestinal manifestations, which require conscientious and diligent monitoring. Peutz-Jeghers syndrome, Cowden syndrome, and juvenile polyposis syndrome are the most common displays of hamartomatous polyposis syndrome (HPS). Diagnosis can be pursued with molecular testing and endoscopic sampling. Early identification of these autosomal dominant pathologies allows to optimize malignancy surveillance, which helps reduce morbidity and mortality in both the affected patient population as well as at-risk family members. Endoscopic surveillance is an important pillar of prognosis and monitoring, with many patients eventually requiring surgical intervention. In this review, we discuss the diagnosis, surveillance, and management of HPS.

**Key Words:** Hamartomatous polyps; Peutz-Jegher syndrome; Cowden syndrome; Juvenile polyposis syndrome

©The Author(s) 2023. Published by Baishideng Publishing Group Inc. All rights reserved.

**Core Tip:** We hope that our review article, "Hamartomatous polyps: Diagnosis, surveillance, and management", will function as a concise review of the literature as pertaining to the diagnosis, surveillance, and treatment of the most common hamartomatous polyp syndromes.

**Citation:** Gorji L, Albrecht P. Hamartomatous polyps: Diagnosis, surveillance, and management. *World J Gastroenterol* 2023; 29(8): 1304-1314

**URL:** <https://www.wjgnet.com/1007-9327/full/v29/i8/1304.htm>

**DOI:** <https://dx.doi.org/10.3748/wjg.v29.i8.1304>

## INTRODUCTION

The national cancer institute defines a hamartoma as, “a benign growth made up of an abnormal mixture of cells and tissues normally found in the area of the body where the growth occurs”[1,2]. Diagnosis may be pursued based on personal or family history, endoscopic evaluation, and histopathology identified on endoscopic tissue sampling. The most common disease processes associated with hamartomatous polyps include Peutz-Jeghers syndromes (PJS), Cowden syndrome (CS), and juvenile polyposis syndrome (JPS). While hamartomatous polyps themselves are benign, diligent surveillance is imperative as a significant risk of malignant transformation exists. Additionally, the disease process is often associated with an increased risk of other additional malignancies. As a result, management often requires multidisciplinary evaluation[1,3]. In this review, we discuss the diagnostic considerations, clinical manifestations, gastrointestinal (GI) and extra-intestinal surveillance recommendations, and management options of the most common syndromes associated with hamartomatous polyps.

## PJS

### Diagnosis

PJS is an autosomal dominant mutation of the mammalian target of rapamycin (mTOR) pathway as a result of a germline mutation of the serine-threonine kinase (*STK11/LKB1*) tumor suppressor gene[4]. The *STK11/LKB1* gene is located on chromosome 19p13.3 and plays an important role in the secondary messenger pathway, which modulates cellular proliferation, responds to cellular energy deficits, and controls cellular polarity[5-7]. The incidence of PJS is estimated to range between approximately 1:8300 and 1:200000 with nearly 70% of cases demonstrating familial inheritance and 30% of cases arising from a sporadic mutation[3,8,9]. Although there is often variable penetrance and clinical heterogeneity, diagnostic clinical criteria include: Any number of polyps with a family history of PJS, two or more Peutz-Jeghers polyps (PJPs), mucocutaneous pigmentations with family history of PJS, or any number of PJPs with mucocutaneous pigmentation[4,8,10]. While endoscopically similar to other polyps, PJPs have a characteristic phyllodes appearing epithelial component and a cystic glandular component which extends into the submucosa and muscular propria on hematoxylin and eosin staining[7,11-13]. Notably, PJPs are exclusively located within the small bowel. Gastric polyps associated with PJS have similar characteristics to hyperplastic gastric polyps and are not considered PJPs[7,12]. The median age of initial polyp development is 12 years-old, with nearly half of patients experiencing symptoms by the age of 20 [7,14]. The primary clinical manifestation of PJS is chronic bleeding from GI polyps leading to anemia. Small bowel obstruction secondary to an intussusception from a hamartomatous polyp of the GI tract occurs in up to 70% of patients, with the average age of diagnosis being 23 years-old[7]. Patients also characteristically present with mucocutaneous hyperpigmentation surrounding the oral cavity, eyes, nostrils, or surrounding the anus[15].

### Surveillance

Due the increased risk of GI and extra-intestinal malignancies, a multidisciplinary approach to screening is encouraged. While the mean age of index cancer diagnosis is 41 years old, PJS is associated with an overall cumulated malignancy rate of 90% by the age of 70[4,8]. GI malignancies commonly associated with PJS include gastric, intestinal, and the pancreatic. Additional extra-intestinal malignancy manifestations include breast, endometrial, ovarian, and lung[11]. Multiple studies have been pursued in order to further characterize the malignancy risk that is associated with PJS (Table 1). The National Comprehensive Cancer Network, European Hereditary Tumour Group, and the American College of Gastroenterology (ACG) provide surveillance recommendations for patients[16-19]. A meticulous regimen of lifelong malignancy surveillance is imperative (Table 2).

### Management

Endoscopy is an essential modality of surveillance and management of polyps associated with PJS. Polypectomy during esophagogastroduodenoscopy (EGD) and colonoscopy is particularly appropriate for patients with a limited number of polyps ranging from 0.5-1 cm in size. If the polyposis that is encountered is too large or numerous to be managed endoscopically, surgical resection of the diseased segment may be pursued[18,20].

**Table 1 Studies investigating the malignancy risk associated with Peutz-Jeghers syndrome**

| Ref.                      | N   | Location       | Outcome                                                                                                                                                                                              |
|---------------------------|-----|----------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Chen <i>et al</i> [80]    | 336 | China          | Patients with PJS possess a 50% cumulative malignancy risk by the age of 60, with the most common malignancy being colorectal cancer at a median age of 41                                           |
| Hearle <i>et al</i> [81]  | 419 | United Kingdom | The risk of developing a malignancy is 85% at the age of 70 in patients with PJS, most common being gastrointestinal in origin                                                                       |
| Ishida <i>et al</i> [82]  | 583 | Japan          | Patients with PJS possess a cumulative malignancy risk of 83% by the age of 70, with an increased rate of gynecologic malignancy in comparison to previously reported data                           |
| Korsse <i>et al</i> [83]  | 144 | Netherlands    | The cumulative risk of pancreatobiliary malignancy is 32% by the age of 70 in patients with PJS                                                                                                      |
| Mehenni <i>et al</i> [84] | 149 | Switzerland    | Patients with PJS have a cumulative malignancy risk of 67% at age 70, particularly with <i>STK11/LKB1</i> mutations in exon 6. Malignancies most commonly occur in the GI tract                      |
| Resta <i>et al</i> [11]   | 119 | Italy          | The <i>STK11/LKB1</i> mutation is associated with a relative overall cancer risk of 15.1, with pancreatic and cervical malignancies being the most common; median age of diagnosis noted to be 41 yr |
| Van Lier <i>et al</i> [8] | 133 | Netherlands    | Patients with PJS possess a cumulative malignancy rate of 76% by the age of 70; malignancies most commonly occur in the GI tract and in women                                                        |

GI: Gastrointestinal; PJS: Peutz-Jeghers syndrome.

**Table 2 Malignancy screening for Peutz-Jeghers syndrome[4,8,10,16-18,85,86]**

| Malignancy  | Screening                                                                                                                                 |
|-------------|-------------------------------------------------------------------------------------------------------------------------------------------|
| Breast      | Annual self-breast exam beginning at the age of 18. Annual breast exam with MRI or mammography beginning at the age of 25, and as needed  |
| Cervical    | Cervical smear annual beginning at the age of 20, and as needed                                                                           |
| Colon       | Colonoscopy every 1-3 yr beginning at the age of 8, and as needed. Routine surveillance at 18 if baseline endoscopy at age 8 is negative  |
| Pancreas    | Annual endoscopic ultrasound or MRCP/ERCP beginning at the age of 30, and as needed                                                       |
| Stomach     | EGD every 1-3 yr beginning at the age of 8, and as needed. Routine surveillance at 18 if baseline endoscopy at age 8 is negative          |
| Small bowel | Capsule endoscopy or CT/MRI enterography every 2-3 yr, beginning at the age of 8, and as needed                                           |
| Testicular  | Annual testicular exam and ultrasound beginning at birth                                                                                  |
| Uterus      | Annual pelvic ultrasound and exam beginning at the age of 25, and as needed; consider total hysterectomy once complete with child-bearing |

MRI: Magnetic resonance imaging; CT: Computed tomography; MRCP: Magnetic resonance pancreatography; ERCP: Endoscopic retrograde cholangiopancreatography; EGD: Esophagogastroduodenoscopy.

Management of small bowel polyps includes double balloon enteroscopy (DBE) or surgery. DBE allows for diagnosis and treatment of polyps located in the jejunum and the ileum. The device possesses a 200 cm long enteroscope with a 145 cm long overtube. There are two latex balloons attached to the tip of the endoscope and overtube, which are managed with a pressure-control pump system serving to prevent redundancy of the small bowel[21-23]. With this approach, manipulation and advancement of the scope may be occasionally impaired in patients who have previously undergone abdominal surgery secondary to intraabdominal adhesions, warranting intraoperative enteroscopy[24,25]. The European Society of Gastrointestinal Endoscopy (ESGE) recommends elective polypectomy for small bowel polyps that are > 15-20 mm in size to reduce the risk of intussusception. In symptomatic patients, polyps that are < 15 mm should be removed, as well[19]. Complications from DBE occur in less than < 1% of cases, but include perforation, post-procedure hemorrhage, pancreatitis and aspiration[23,26]. DBE is an effective method for early detection and non-operative removal of polyps located in the small bowel[18, 27]. Similar to polyposis of the colon, surgical resection may be required in the setting of numerous or large polyposis of the small bowel[19].

Surgical intervention is required for patients with PJS who present with intussusception, a phenomenon where the proximal segment of bowel telescopes into a distal segment of bowel with the polyp acting as a lead point. If no intervention is pursued, bowel ischemia and perforation may occur [4]. Patients with PJS possess a cumulative risk of intussusception reaching nearly 44% by the age of 10,

which increases to nearly 50% by the age of 20[20]. The risk of intussusception is greatest with polyps that are 15 mm or larger[28]. Intraoperatively, frankly ischemic bowel evidently must be removed; however, polypectomy without bowel resection is recommended in cases of reversible ischemia. As the risk of recurrent intussusception is present especially in younger patients, some authors have recommended further evaluate the bowel through manual palpation or enteroscopy *via* an intraoperative enterotomy in order to remove any additional polyps greater than 15 mm[20,29].

According to the ESGE, pancreatic lesions should be addressed with partial pancreatectomies in the case of: (1) Solid lesions  $\geq 10$  mm unless known to be benign; or (2) intraductal papillary mucinous neoplasms with high-risk features including mural nodules, enhanced solid component, obstructive symptoms, enhanced cyst wall, abrupt changes to duct size, and main pancreatic duct  $\geq 10$  mm[19,30].

Breast lesions should be managed based on current breast cancer guidelines, as no therapeutic strategy specific to PJS is presently available. A mastectomy for the purpose of risk reduction should be discussed in a multi-disciplinary setting accounting for additional patient risk factors and family history [19]. Similarly, while an established malignancy risk exists between PJS and cervical, uterine, and testicular cancer, no formal intervention guidelines specific to the correlation exists.

Studies have also demonstrated that the immunosuppressant agent Sirolimus (Rapamycin) has led to reduction in the number and size of polyps in a mouse model, which is largely attribute to the anti-angiogenic properties of the drug[31-33]. Currently, phase 4 prospective study for characterization of the drug in patients with PJS is being undertaken.

## CS

### Diagnosis

CS is an autosomal dominant mutation in the *phosphatase and tensin homolog (PTEN)* gene impacting the downregulation of the mTOR pathway. Consequently, the *PTEN* regulation of cellular proliferation and survival is impaired[34,35]. The incidence of CS is estimated to be roughly 1:200000[36]. CS characteristically presents with hamartomatous polyps which may appear in any organ. Nearly all patients exhibit some type of skin lesion including trichilemmomas, acral keratoses, and papillomatous papules. Additionally, nearly 80% of patients demonstrate GI hamartomatous polyps and 80% of patients exhibit macrocephaly. Diagnosis is based on the guidelines established by the International CS Consortium: Patients must possess two major criteria one of which must be either macrocephaly or Lhermitte-Duclos disease (LDD), one major criteria with three minor criteria, or four minor criteria (Table 3)[37]. 40% of CS is associated with LDD—a rare, slow growing dysplastic gangliocytoma of the cerebellum manifesting with a broad range of clinical findings. The presentation of LDD may range from being asymptomatic to exhibiting signs of ataxia, cranial nerve palsy, vertigo, mental impairment and deterioration, intracranial hypertension, and hydrocephalus. The wide spectrum of clinical manifestations is attributable to the slow growing nature of the neoplasm[38,39].

### Surveillance

The majority of patients with CS are at risk for developing breast, thyroid, renal, endometrial, colorectal, and skin malignancies (Table 4). Given this established predisposition, attentive multidisciplinary surveillance and screening is an essential component of disease management (Table 5). The purpose of these surveillance recommendations is early detection in order to allow curative oncologic treatment.

### Management

There is no available curative treatment for CS. Rather, management is geared towards early detection of malignancy and timely oncologic treatment. Genetic counseling is also prudent in order to promote early detection and surveillance for kindred. Options for treatment of cutaneous lesions include, surgical excision, 5-Fluorouracil, carbon dioxide laser treatments, isotretinoin[40,41]. Polyps found on endoscopy may be removed endoscopically, if amenable. Otherwise, identified malignancies should be addressed utilizing the most up-to-date therapeutic regimens.

### Associated syndromes

*PTEN* hamartoma tumor syndrome (PHTS) is a broad category of hamartomatous pathologies arising as pathogenic *PTEN* mutation variants identified by gene-targeted testing and comprehensive genomic testing. PHTS classically includes CS, Bannayan-Riley-Ruvalcaba Syndromes (BRRS), *PTEN*-related Proteus Syndromes (PS), and *PTEN*-related Proteus-like syndromes (PLS). Notably, however, segmental overgrowth lipomatosis arteriovenous malformation epidermal nevus (SOLAMEN) syndrome also shares the same mutation[42,43]. It has been proposed that CS and BRRS may simply be varying spectrums of the same syndrome[44]. While formal diagnosis criteria are not present for BRRS, patients often present with macrocephaly, penile mucocutaneous lesions, delayed psychomotor development, and visceral hamartomas[44,45]. Approximately half of patients with BRRS have GI polyposis, with an analogous histopathologic presentation[44]. Nearly 60% of patients with BRRS possess a germline *PTEN*

**Table 3 Major and minor criteria for the diagnosis of Cowden syndrome[37]**

| Major criteria           | Minor criteria                        |
|--------------------------|---------------------------------------|
| Breast malignancy        | Fibrocystic changes of the breast     |
| Lhermitte-Duclos disease | Fibromas                              |
| Macrocephaly             | Gastrointestinal hamartomas           |
| Thyroid malignancy       | Genitourinary tumors or malformations |
|                          | Lipomas                               |
|                          | Mental retardation                    |
|                          | Thyroid lesions, <i>i.e.</i> goiter   |

**Table 4 Studies investigating the malignancy risk associated with *phosphatase and tensin homolog* mutation**

| Ref.                         | N    | Location                        | Outcome                                                                                                                                                                                                                         |
|------------------------------|------|---------------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Tan <i>et al</i> [87]        | 3399 | North America, Europe, and Asia | Patient with <i>PTEN</i> mutations possess a lifetime breast cancer risk of 85%, thyroid cancer risk of 35%, renal cell carcinoma of 35%, endometrial cancer risk of 28%, colorectal cancer risk of 9%, and melanoma risk of 6% |
| Fackenthal <i>et al</i> [88] | 2    | United States                   | There is an increased risk of male breast cancer in patient with <i>PTEN</i> mutations and CS                                                                                                                                   |
| Harach <i>et al</i> [89]     | 11   | Argentina                       | Patients with CS have increased likelihood of developing benign thyroid lesions, with increased risk of malignant transformation                                                                                                |
| Ngeow <i>et al</i> [90]      | 2723 | United States                   | CS and CS-like phenotypes possess standardized incidence rate for thyroid cancer of 72%, particularly follicular thyroid cancer                                                                                                 |
| Heald <i>et al</i> [91]      | 127  | North America and Europe        | <i>PTEN</i> mutations are associated with early-onset (age < 50) colorectal malignancy; routine colonoscopy should be encouraged                                                                                                |

*PTEN*: *Phosphatase and tensin homolog*; CS: Cowden syndrome.

**Table 5 Malignancy screening for *phosphatase and tensin homolog* mutation[92]**

| Malignancy  | Screening                                                                                                           |
|-------------|---------------------------------------------------------------------------------------------------------------------|
| Breast      | Annual self-breast exam at the age of 18; annual clinical breast exam at the age of 25; annual MRI at the age of 30 |
| Colon       | Colonoscopy every 5 yr at the age of 35, and as needed                                                              |
| Endometrial | Annual exam with biopsy at the age of 35, and as needed. Hysterectomy upon childbearing completion                  |
| Kidney      | Annual renal ultrasound at the age of 40; CT or MRI as indicated                                                    |
| Skin lesion | Annual dermatologic exams, no consensus on initiation age                                                           |
| Thyroid     | Annual thyroid ultrasound at the age of 7                                                                           |

MRI: Magnetic resonance imaging; CT: Computed tomography.

mutation[46]. SOLAMEN syndrome is also associated with hamartomatous polyps, macrocephaly, lipomas, and hemangiomas. These patients further possess an increased risk of skin, GI, thyroid, breast, brain, and genito-urinary malignant neoplasms[47,48]. Surveillance is advised to be similar to CS, given the mutual *PTEN* mutation association (Table 5). Treatment is predominantly symptomatic and often requires a multidisciplinary approach[49].

PS and PLS are similar pathologic processes that may be associated with a *PTEN* mutations[50]. PS has been associated with *AKT1* and *PTEN* mutations, both of which influence the PI3KCA/AKT pathway[51]. Pulmonary embolism secondary to a hypercoagulable state and pneumonia are noted to be contributing factors to early mortality in this patient population. Other complications include scoliosis, central nervous system abnormalities, ophthalmic complications, abnormal bone growth, and pulmonary malformations[52]. Treatment is often targeted toward the correction of the functional limitations caused by the skeletal deformities associated with the disease. Patients should be closely monitored for the development of venous thrombosis; however, no recommendations for prophylactic anticoagulation currently exist[3,53]. Patients that have presentations similar to PS, but do not possess

all the diagnostic criteria are deemed to have PLS.

## JPS

### Diagnosis

JPS is an autosomal dominant condition resulting from a germline mutation of the *SMAD4* or *BMPR1A* genes in 60% of the affected population. These genes impact the transforming growth factor-beta signaling pathway[54,55]. The estimated incidence of JPS is approximately between 1:100000 to 1:160000 [56,57]. Clinical diagnosis is based on the presence of one of the following: 5+ juvenile polyps in the colorectal region, 2+ juvenile polyps in the GI tract, or any number of juvenile polyps with a family history of juvenile polyposis[18,56,58,59]. Juvenile polyps refer to the histopathology of the polyps, rather than the age of onset. Juvenile polyps are hamartomas demonstrating a dense stroma with a smooth surface and mucin-filled cystic lamina propria[60]. Macroscopically, these pedunculated polyps have an erosive surface ranging from 5 mm to 50 mm in size. While distinction with sporadic juvenile polyps is difficult to make, JPS polyps frequently demonstrate epithelial neoplastic transformation, reduced stroma, reduced dilated glands, and increased proliferative glands[61].

Subtypes of JPS include JPS of infancy, generalized JPS, and juvenile polyposis coli. JPS of infancy is characterized by sessile or pedunculated polyps diffusely throughout the GI tract ranging from 1-30 mm. Although further investigation must be pursued, some sources have reported JPS of infancy is caused by mutations resulting in the continuous deletion of *BMPR1A* and *PTEN*[62]. The disease process is plagued with early mortality secondary to hemorrhage, malnutrition caused by diarrhea, and intussusception[61,63]. Considered to be a variable spectrum of penetrance of the same disease, generalized JPS occurs diffusely throughout the GI tract while juvenile polyposis coli is limited to the colorectal region[64]. Nearly half of the patients with generalized JPS or juvenile polyposis coli possess a heterozygous germline mutation of the *SMAD4* or *BMPR1A* gene[64].

Extra-intestinal manifestations are present in up to 15% of patients including midgut rotation, cardiac abnormalities, and craniofacial abnormalities. JPS may also be present in conjunction to hereditary hemorrhagic telangiectasia (HHT) syndrome[65,66]. Patients with HHT have a characteristic increased risk of bleeding secondary to greater rates of arteriovenous malformations of the lung, liver, brain, and GI tract. HHT is an autosomal dominant disorder also associated with a *SMAD4* gene mutation[65,67,68]. Patient may demonstrate varying degrees of disease qualities when they have both disorders simultaneously. However, the combination of both disorders results in a higher risk of colorectal malignant neoplasms and anemia[68,69]. Although further studies are required, the current perspective on the malignant pathogenesis of JPS includes the “landscaper mechanism” and the “gatekeeper” model. The “landscaper mechanism” postulates that genetic alterations lead to an abnormal stromal environment, which leads to malignant transformation of neighboring epithelium. A *de novo* study by Haramis *et al*[70] demonstrated that bone morphogenetic protein (*BMP*)-4 inhibition, a common JPS pathway mutation, results in ectopic crypt units adjacent to the crypt-villus axis supporting the “landscaper mechanism”[70]. A “gatekeeper” model has also been proposed, where the biallelic *SMAD4* mutation contributes to malignant transformation and progression[71,72].

### Surveillance

JPS has an established increased risk of GI malignancy, with a cumulative lifetime risk reported to range between 39%-63%[73,74]. The *SMAD4* gene has been associated with a greater risk of GI malignancies as well as a greater number of polyps in comparison to the *BMPR1A* mutation[54,75,76]. JPS is associated with an elevated risk of colorectal and gastric malignancies (Table 6). Therefore, a combination of colonoscopy and EGD is recommended for appropriate screening and surveillance[77] (Table 7).

### Management

Endoscopic management is typically feasible for patients with a limited number of polyps[18]. EGD may be utilized for surveillance and endoscopic removal of polyps located in the stomach and duodenum. In the setting of extensive polyposis, advanced dysplasia, or malignancy, a partial or complete gastrectomy may be pursued[44,78] Jaoude *et al*[55] recommended proposed prophylactic gastrectomy in patients with symptomatic JPS, asymptomatic patients with a *SMAD4* mutation, or patients with unmanageable polyposis defined as > 50-100 polyps[55]. Certainly, morbidity and mortality are greater with surgical intervention. However, surgical intervention must be weighed against the possibility of inadequate surveillance and treatment with endoscopy, particularly in the setting of an elevated likelihood for sporadic gastric malignancy associated with the *SMAD4* gene mutation. Further investigation should be pursued to determine the optimal parameters for surgical intervention, particularly in the prophylactic setting.

Small bowel polyps should be evaluated periodically with enteroscopy. Patient with limited small bowel polyps may be managed with endoscopic polypectomy but will require surgical treatment in the event of obstructive symptoms associated with intussusception. Colonoscopy is an essential screening and management tool for colonic polyps. However, in the setting of numerous polyps, advanced

**Table 6 Studies investing the malignancy risk associated with juvenile polyposis syndrome**

| Ref.                        | N   | Location       | Outcome                                                                                                                                          |
|-----------------------------|-----|----------------|--------------------------------------------------------------------------------------------------------------------------------------------------|
| Brosens <i>et al</i> [73]   | 84  | United States  | Patients with JPS possess a lifetime cumulative risk of 38.7% for development of colorectal cancer, with the average age of diagnosis being 43.9 |
| Latchford <i>et al</i> [56] | 44  | United Kingdom | The <i>SMAD4</i> gene is a poor prognostic indicator for development of gastric malignancy. Colonic polyps have predominance to ascending colon  |
| Howe <i>et al</i> [93]      | 117 | United States  | Kindred of patients with JPS possess approximately 50% cumulative risk of developing gastric malignancy                                          |

JPS: Juvenile polyposis syndrome.

**Table 7 Malignancy screening for juvenile polyposis syndrome[18,77,94-96]**

| Malignancy   | Screening                                                                                                                           |
|--------------|-------------------------------------------------------------------------------------------------------------------------------------|
| Colorectal   | Colonoscopy every 1-3 yr between the ages of 12-15; screening should be initiated sooner if earlier onset of symptoms               |
| Gastric      | Esophagogastroduodenoscopy every 1-3 yr between the age of 12-15; screening should be initiated sooner if earlier onset of symptoms |
| HHT mutation | Brain MRI, cardiac echocardiogram, testing for lung arterio-venous malformations                                                    |

HHT: Hereditary hemorrhagic telangiectasia; MRI: Magnetic resonance imaging.

dysplasia, or malignancy, a colectomy may be pursued. Surgical options include proctocolectomy with ileal pouch anal anastomosis (IPAA) or colectomy with ileorectal anastomosis (IRA) based on rectal involvement. Nearly half of patients who elect to undergo IRA will require additional proctocolectomy with IPAA secondary to the development of rectal polyposis[18,44,78].

An area of potential emerging investigation includes the utility of chemoprevention in patients with JPS. Van Hattem *et al*[79] determined an increased expression of cyclooxygenase-2, particularly in patients with a *BMPRI1A* gene mutation. Further investigation should be pursued in order to determine the clinical implications of this expression profile[79]. Ultimately, additional studies should be pursued regarding the optimal management of these patients.

## CONCLUSION

Hamartomas polyps result from hyperproliferations of normal tissues and are often associated with genetic mutations. While patients experience symptoms from the hamartomas themselves, there also exists an established malignancy risk associated with these disorders. Therefore, patient education regarding surveillance is imperative, and a multidisciplinary approach is often required for comprehensive management. First degree relatives should also be investigated for the diagnosis due to the dominant inheritance patterns that these disease processes possess. Due to the rarity of the disorders, limited studies are available on the clinical and molecular aspects of the disease processes, and further investigation should be dedicated to understanding the pathology associated with these syndromes.

## FOOTNOTES

**Author contributions:** Gorji L and Albrecht P performed the conceptualization; Gorji L wrote the original draft; Gorji L and Albrecht P contributed to the reviewing and editing; All authors have read and agreed to the published version of the manuscript.

**Conflict-of-interest statement:** All the authors report no relevant conflicts of interest for this article.

**Open-Access:** This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: <https://creativecommons.org/licenses/by-nc/4.0/>

**Country/Territory of origin:** United States

ORCID number: Leva Gorji 0000-0001-6837-5317.

S-Editor: Fan JR

L-Editor: A

P-Editor: Fan JR

## REFERENCES

- 1 Cauchin E, Toucheffeu Y, Matysiak-Budnik T. Hamartomatous Tumors in the Gastrointestinal Tract. *Gastrointest Tumors* 2015; **2**: 65-74 [PMID: 26672891 DOI: 10.1159/000437175]
- 2 NIH. Hamartoma. [cited 10 October 2022]. Available from: <https://www.cancer.gov/publications/dictionaries/cancer-terms/def/hamartoma>
- 3 Jelsig AM, Qvist N, Brusgaard K, Nielsen CB, Hansen TP, Ousager LB. Hamartomatous polyposis syndromes: a review. *Orphanet J Rare Dis* 2014; **9**: 101 [PMID: 25022750 DOI: 10.1186/1750-1172-9-101]
- 4 Gorji L, Huish G, Morgan J, Levy P. A case of sporadic Peutz-Jeghers syndrome presenting as multiple intussusceptions. *J Surg Case Rep* 2022; **2022**: rjac070 [PMID: 35280052 DOI: 10.1093/jscr/rjac070]
- 5 Miyaki M. [Peutz-Jeghers syndrome]. *Nihon Rinsho* 2000; **58**: 1400-1404 [PMID: 10921312]
- 6 Zbuk KM, Eng C. Hamartomatous polyposis syndromes. *Nat Clin Pract Gastroenterol Hepatol* 2007; **4**: 492-502 [PMID: 17768394 DOI: 10.1038/ncpgasthep0902]
- 7 Kopacova M, Tachei I, Rejchrt S, Bures J. Peutz-Jeghers syndrome: diagnostic and therapeutic approach. *World J Gastroenterol* 2009; **15**: 5397-5408 [PMID: 19916169 DOI: 10.3748/wjg.15.5397]
- 8 van Lier MG, Westerman AM, Wagner A, Looman CW, Wilson JH, de Rooij FW, Lemmens VE, Kuipers EJ, Mathus-Vliegen EM, van Leerdam ME. High cancer risk and increased mortality in patients with Peutz-Jeghers syndrome. *Gut* 2011; **60**: 141-147 [PMID: 21205875 DOI: 10.1136/gut.2010.223750]
- 9 McGarrity TJ, Amos C. Peutz-Jeghers syndrome: clinicopathology and molecular alterations. *Cell Mol Life Sci* 2006; **63**: 2135-2144 [PMID: 16952058 DOI: 10.1007/s00018-006-6080-0]
- 10 Beggs AD, Latchford AR, Vasen HF, Moslein G, Alonso A, Aretz S, Bertario L, Blanco I, Bülow S, Burn J, Capella G, Colas C, Friedl W, Möller P, Hes FJ, Järvinen H, Mecklin JP, Nagengast FM, Parc Y, Phillips RK, Hyer W, Ponz de Leon M, Renkonen-Sinisalo L, Sampson JR, Stormorken A, Tejpar S, Thomas HJ, Wijnen JT, Clark SK, Hodgson SV. Peutz-Jeghers syndrome: a systematic review and recommendations for management. *Gut* 2010; **59**: 975-986 [PMID: 20581245 DOI: 10.1136/gut.2009.198499]
- 11 Resta N, Pierannunzio D, Lenato GM, Stella A, Capocaccia R, Bagnulo R, Lastella P, Susca FC, Bozzao C, Loconte DC, Sabbà C, Urso E, Sala P, Fornasari M, Grammatico P, Piepoli A, Host C, Turchetti D, Viel A, Memo L, Giunti L, Stigliano V, Varesco L, Bertario L, Genuardi M, Lucci Cordisco E, Tibiletti MG, Di Gregorio C, Andriulli A, Ponz de Leon M; AIFEG. Cancer risk associated with STK11/LKB1 germline mutations in Peutz-Jeghers syndrome patients: results of an Italian multicenter study. *Dig Liver Dis* 2013; **45**: 606-611 [PMID: 23415580 DOI: 10.1016/j.dld.2012.12.018]
- 12 Burkart AL, Sheridan T, Lewin M, Fenton H, Ali NJ, Montgomery E. Do sporadic Peutz-Jeghers polyps exist? *Am J Surg Pathol* 2007; **31**: 1209-1214 [PMID: 17667545 DOI: 10.1097/PAS.0b013e3180339944]
- 13 Lynch HT, Lynch JF, Lynch PM, Attard T. Hereditary colorectal cancer syndromes: molecular genetics, genetic counseling, diagnosis and management. *Fam Cancer* 2008; **7**: 27-39 [PMID: 17999161 DOI: 10.1007/s10689-007-9165-5]
- 14 Hinds R, Philp C, Hyer W, Fell JM. Complications of childhood Peutz-Jeghers syndrome: implications for pediatric screening. *J Pediatr Gastroenterol Nutr* 2004; **39**: 219-220 [PMID: 15269641 DOI: 10.1097/00005176-200408000-00027]
- 15 McGarrity TJ, Amos CI, Baker MJ. Peutz-Jeghers Syndrome. 2001 Feb 23. In: GeneReviews® [Internet]. Seattle (WA): University of Washington, Seattle; 1993– [PMID: 20301443]
- 16 van Leerdam ME, Roos VH, van Hooft JE, Dekker E, Jover R, Kaminski MF, Latchford A, Neumann H, Pellisé M, Saurin JC, Tanis PJ, Wagner A, Balaguer F, Ricciardiello L. Endoscopic management of polyposis syndromes: European Society of Gastrointestinal Endoscopy (ESGE) Guideline. *Endoscopy* 2019; **51**: 877-895 [PMID: 31342472 DOI: 10.1055/a-0965-0605]
- 17 NCCN. Genetic/Familial High-Risk Assessment: Colorectal, Version 1.2022. [cited 10 October 2022]. Available from: <https://facultyopinions.com/article/726636043#eval793526248>
- 18 Syngal S, Brand RE, Church JM, Giardiello FM, Hampel HL, Burt RW; American College of Gastroenterology. ACG clinical guideline: Genetic testing and management of hereditary gastrointestinal cancer syndromes. *Am J Gastroenterol* 2015; **110**: 223-62; quiz 263 [PMID: 25645574 DOI: 10.1038/ajg.2014.435]
- 19 Wagner A, Aretz S, Auranen A, Bruno MJ, Cavestro GM, Crosbie EJ, Goverde A, Jelsig AM, Latchford A, Leerdam MEV, Lepisto A, Puzzono M, Winship I, Zuber V, Möslin G. The Management of Peutz-Jeghers Syndrome: European Hereditary Tumour Group (EHTG) Guideline. *J Clin Med* 2021; **10** [PMID: 33513864 DOI: 10.3390/jcm10030473]
- 20 van Lier MG, Mathus-Vliegen EM, Wagner A, van Leerdam ME, Kuipers EJ. High cumulative risk of intussusception in patients with Peutz-Jeghers syndrome: time to update surveillance guidelines? *Am J Gastroenterol* 2011; **106**: 940-945 [PMID: 21157440 DOI: 10.1038/ajg.2010.473]
- 21 Yano T, Yamamoto H. Vascular, polypoid, and other lesions of the small bowel. *Best Pract Res Clin Gastroenterol* 2009; **23**: 61-74 [PMID: 19258187 DOI: 10.1016/j.bpg.2008.12.001]
- 22 Saygili F, Saygili SM, Oztas E. Examining the whole bowel, double balloon enteroscopy: Indications, diagnostic yield and complications. *World J Gastrointest Endosc* 2015; **7**: 247-252 [PMID: 25789095 DOI: 10.4253/wjge.v7.i3.247]
- 23 Chen WG, Shan GD, Zhang H, Yang M, L L, Yue M, Chen GW, Gu Q, Zhu HT, Xu GQ, Chen LH. Double-balloon enteroscopy in small bowel diseases: Eight years single-center experience in China. *Medicine (Baltimore)* 2016; **95**: e5104

- [PMID: 27759639 DOI: 10.1097/MD.00000000000005104]
- 24 **Mönkemüller K**, Weigt J, Treiber G, Kolffenbach S, Kahl S, Röcken C, Ebert M, Fry LC, Malfertheiner P. Diagnostic and therapeutic impact of double-balloon enteroscopy. *Endoscopy* 2006; **38**: 67-72 [PMID: 16429357 DOI: 10.1055/s-2005-921190]
  - 25 **Fraser JD**, Briggs SE, St Peter SD, De Petris G, Heppell J. Intussusception in the adult: an unsuspected case of Peutz-Jeghers syndrome with review of the literature. *Fam Cancer* 2009; **8**: 95-101 [PMID: 18726167 DOI: 10.1007/s10689-008-9212-x]
  - 26 **Gerson LB**, Tokar J, Chiorean M, Lo S, Decker GA, Cave D, Bouhaidar D, Mishkin D, Dye C, Haluszka O, Leighton JA, Zfass A, Semrad C. Complications associated with double balloon enteroscopy at nine US centers. *Clin Gastroenterol Hepatol* 2009; **7**: 1177-1182, 1182.e1 [PMID: 19602453 DOI: 10.1016/j.cgh.2009.07.005]
  - 27 **May A**, Nachbar L, Ell C. Double-balloon enteroscopy (push-and-pull enteroscopy) of the small bowel: feasibility and diagnostic and therapeutic yield in patients with suspected small bowel disease. *Gastrointest Endosc* 2005; **62**: 62-70 [PMID: 15990821 DOI: 10.1016/s0016-5107(05)01586-5]
  - 28 **Latchford A**, Cohen S, Auth M, Scaillon M, Viala J, Daniels R, Talbotec C, Attard T, Durno C, Hyer W. Management of Peutz-Jeghers Syndrome in Children and Adolescents: A Position Paper From the ESPGHAN Polyposis Working Group. *J Pediatr Gastroenterol Nutr* 2019; **68**: 442-452 [PMID: 30585892 DOI: 10.1097/MPG.0000000000002248]
  - 29 **Edwards DP**, Khosraviani K, Stafferton R, Phillips RK. Long-term results of polyp clearance by intraoperative enteroscopy in the Peutz-Jeghers syndrome. *Dis Colon Rectum* 2003; **46**: 48-50 [PMID: 12544521 DOI: 10.1007/s10350-004-6495-3]
  - 30 **Canto MI**, Harinck F, Hruban RH, Offerhaus GJ, Poley JW, Kamel I, Nio Y, Schulick RS, Bassi C, Kluijdt I, Levy MJ, Chak A, Fockens P, Goggins M, Bruno M; International Cancer of Pancreas Screening (CAPS) Consortium. International Cancer of the Pancreas Screening (CAPS) Consortium summit on the management of patients with increased risk for familial pancreatic cancer. *Gut* 2013; **62**: 339-347 [PMID: 23135763 DOI: 10.1136/gutjnl-2012-303108]
  - 31 **Wei C**, Amos CI, Zhang N, Zhu J, Wang X, Frazier ML. Chemopreventive efficacy of rapamycin on Peutz-Jeghers syndrome in a mouse model. *Cancer Lett* 2009; **277**: 149-154 [PMID: 19147279 DOI: 10.1016/j.canlet.2008.11.036]
  - 32 **Wei C**, Amos CI, Zhang N, Wang X, Rashid A, Walker CL, Behringer RR, Frazier ML. Suppression of Peutz-Jeghers polyposis by targeting mammalian target of rapamycin signaling. *Clin Cancer Res* 2008; **14**: 1167-1171 [PMID: 18281551 DOI: 10.1158/1078-0432.CCR-07-4007]
  - 33 **Robinson J**, Lai C, Martin A, Nye E, Tomlinson I, Silver A. Oral rapamycin reduces tumour burden and vascularization in Lkb1(+/-) mice. *J Pathol* 2009; **219**: 35-40 [PMID: 19434632 DOI: 10.1002/path.2562]
  - 34 **Garofola C**, Gross GP. Hamartoma, Cowden Disease (Multiple Hamartoma Syndrome). *StatPearls* 2018 [DOI: 10.1016/b978-1-4160-5544-0.00174-4]
  - 35 **Gammon A**, Jaspersen K, Champine M. Genetic basis of Cowden syndrome and its implications for clinical practice and risk management. *Appl Clin Genet* 2016; **9**: 83-92 [PMID: 27471403 DOI: 10.2147/TACG.S41947]
  - 36 **Uppal S**, Mistry D, Coatesworth AP. Cowden disease: a review. *Int J Clin Pract* 2007; **61**: 645-652 [PMID: 17394437 DOI: 10.1111/j.1742-1241.2006.00896.x]
  - 37 **Pilarski R**, Burt R, Kohlman W, Pho L, Shannon KM, Swisher E. Cowden syndrome and the PTEN hamartoma tumor syndrome: systematic review and revised diagnostic criteria. *J Natl Cancer Inst* 2013; **105**: 1607-1616 [PMID: 24136893 DOI: 10.1093/jnci/djt277]
  - 38 **Giorgianni A**, Pellegrino C, De Benedictis A, Mercuri A, Baruzzi F, Minotto R, Tabano A, Balbi S. Lhermitte-Duclos disease. A case report. *Neuroradiol J* 2013; **26**: 655-660 [PMID: 24355184 DOI: 10.1177/197140091302600608]
  - 39 **Buhl R**, Barth H, Hugo HH, Straube T, Mehdorn HM. Dysplastic gangliocytoma of the cerebellum: rare differential diagnosis in space occupying lesions of the posterior fossa. *Acta Neurochir (Wien)* 2003; **145**: 509-12; discussion 512 [PMID: 12836078 DOI: 10.1007/s00701-003-0040-3]
  - 40 **Iacobas I**, Burrows PE, Adams DM, Sutton VR, Hollier LH, Chintagumpala MM. Oral rapamycin in the treatment of patients with hamartoma syndromes and PTEN mutation. *Pediatr Blood Cancer* 2011; **57**: 321-323 [PMID: 21360661 DOI: 10.1002/pbc.23098]
  - 41 **Wheeland RG**, McGillis ST. Cowden's disease--treatment of cutaneous lesions using carbon dioxide laser vaporization: a comparison of conventional and superpulsed techniques. *J Dermatol Surg Oncol* 1989; **15**: 1055-1059 [PMID: 2794201 DOI: 10.1111/j.1524-4725.1989.tb03122.x]
  - 42 **Yehia L**, Ni Y, Feng F, Seyfi M, Sadler T, Frazier TW, Eng C. Distinct Alterations in Tricarboxylic Acid Cycle Metabolites Associate with Cancer and Autism Phenotypes in Cowden Syndrome and Bannayan-Riley-Ruvalcaba Syndrome. *Am J Hum Genet* 2019; **105**: 813-821 [PMID: 31564436 DOI: 10.1016/j.ajhg.2019.09.004]
  - 43 **Buxbaum JD**, Cai G, Chaste P, Nygren G, Goldsmith J, Reichert J, Anckarsäter H, Rastam M, Smith CJ, Silverman JM, Hollander E, Leboyer M, Gillberg C, Verloes A, Betancur C. Mutation screening of the PTEN gene in patients with autism spectrum disorders and macrocephaly. *Am J Med Genet B Neuropsychiatr Genet* 2007; **144B**: 484-491 [PMID: 17427195 DOI: 10.1002/ajmg.b.30493]
  - 44 **Schreibman IR**, Baker M, Amos C, McGarrity TJ. The hamartomatous polyposis syndromes: a clinical and molecular review. *Am J Gastroenterol* 2005; **100**: 476-490 [PMID: 15667510 DOI: 10.1111/j.1572-0241.2005.40237.x]
  - 45 **Vyas M**, Yang X, Zhang X. Gastric Hamartomatous Polyps-Review and Update. *Clin Med Insights Gastroenterol* 2016; **9**: 3-10 [PMID: 27081323 DOI: 10.4137/CGast.S38452]
  - 46 **Marsh DJ**, Coulon V, Lunetta KL, Rocca-Serra P, Dahia PL, Zheng Z, Liaw D, Caron S, Duboué B, Lin AY, Richardson AL, Bonnetblanc JM, Bressieux JM, Cabarro-Moreau A, Chompret A, Demange L, Eeles RA, Yahanda AM, Fearon ER, Fricker JP, Gorlin RJ, Hodgson SV, Huson S, Lacombe D, Eng C. Mutation spectrum and genotype-phenotype analyses in Cowden disease and Bannayan-Zonana syndrome, two hamartoma syndromes with germline PTEN mutation. *Hum Mol Genet* 1998; **7**: 507-515 [PMID: 9467011 DOI: 10.1093/hmg/7.3.507]
  - 47 **Zhou X**, Hampel H, Thiele H, Gorlin RJ, Hennekam RC, Parisi M, Winter RM, Eng C. Association of germline mutation in the PTEN tumour suppressor gene and Proteus and Proteus-like syndromes. *Lancet* 2001; **358**: 210-211 [PMID: 11476841 DOI: 10.1016/s0140-6736(01)05412-5]

- 48 **Gupta SK**, Sushantika, Abdelmaksoud A. Isolated SOLAMEN Syndrome. *Indian J Dermatol* 2021; **66**: 561-563 [PMID: 35068519 DOI: 10.4103/ijd.IJD\_675\_20]
- 49 **Caux F**, Plauchu H, Chibon F, Faivre L, Fain O, Vabres P, Bonnet F, Selma ZB, Laroche L, Gérard M, Longy M. Segmental overgrowth, lipomatosis, arteriovenous malformation and epidermal nevus (SOLAMEN) syndrome is related to mosaic PTEN nullizygosity. *Eur J Hum Genet* 2007; **15**: 767-773 [PMID: 17392703 DOI: 10.1038/sj.ejhg.5201823]
- 50 **Smith JM**, Kirk EP, Theodosopoulos G, Marshall GM, Walker J, Rogers M, Field M, Brereton JJ, Marsh DJ. Germline mutation of the tumour suppressor PTEN in Proteus syndrome. *J Med Genet* 2002; **39**: 937-940 [PMID: 12471211 DOI: 10.1136/jmg.39.12.937]
- 51 **Lindhurst MJ**, Sapp JC, Teer JK, Johnston JJ, Finn EM, Peters K, Turner J, Cannons JL, Bick D, Blakemore L, Blumhorst C, Brockmann K, Calder P, Cherman N, Deardorff MA, Everman DB, Golas G, Greenstein RM, Kato BM, Keppler-Noreuil KM, Kuznetsov SA, Miyamoto RT, Newman K, Ng D, O'Brien K, Rothenberg S, Schwartzentruber DJ, Singhal V, Tirabosco R, Upton J, Wientroub S, Zackai EH, Hoag K, Whitewood-Neal T, Robey PG, Schwartzberg PL, Darling TN, Tosi LL, Mullikin JC, Biesecker LG. A mosaic activating mutation in AKT1 associated with the Proteus syndrome. *N Engl J Med* 2011; **365**: 611-619 [PMID: 21793738 DOI: 10.1056/NEJMoa1104017]
- 52 **Turner JT**, Cohen MM Jr, Biesecker LG. Reassessment of the Proteus syndrome literature: application of diagnostic criteria to published cases. *Am J Med Genet A* 2004; **130A**: 111-122 [PMID: 15372514 DOI: 10.1002/ajmg.a.30327]
- 53 **Rocha RCC**, Estrella MPS, Amaral DMD, Barbosa AM, Abreu MAMM. Proteus syndrome. *An Bras Dermatol* 2017; **92**: 717-720 [PMID: 29166516 DOI: 10.1590/abd1806-4841.20174496]
- 54 **Rosty C**. The Role of the Surgical Pathologist in the Diagnosis of Gastrointestinal Polyposis Syndromes. *Adv Anat Pathol* 2018; **25**: 1-13 [PMID: 28901964 DOI: 10.1097/PAP.0000000000000173]
- 55 **Jaoude JB**, Hallit R, Rassy EE, Abboud B. The role of prophylactic gastrectomy in patients with juvenile polyposis syndrome. *Clin Res Hepatol Gastroenterol* 2019; **43**: e42-e43 [PMID: 30217482 DOI: 10.1016/j.clinre.2018.08.011]
- 56 **Latchford AR**, Neale K, Phillips RK, Clark SK. Juvenile polyposis syndrome: a study of genotype, phenotype, and long-term outcome. *Dis Colon Rectum* 2012; **55**: 1038-1043 [PMID: 22965402 DOI: 10.1097/DCR.0b013e31826278b3]
- 57 **Dal Buono A**, Gaiani F, Poliani L, Laghi L. Juvenile polyposis syndrome: An overview. *Best Pract Res Clin Gastroenterol* 2022; **58-59**: 101799 [PMID: 35988962 DOI: 10.1016/j.bpg.2022.101799]
- 58 **Gilad O**, Rosner G, Fliss-Isakov N, Aharon-Kaspi S, Strul H, Gluck N, Kariv R. Clinical and Histologic Overlap and Distinction Among Various Hamartomatous Polyposis Syndromes. *Clin Transl Gastroenterol* 2019; **10**: 1-9 [PMID: 31107726 DOI: 10.14309/ctg.0000000000000035]
- 59 **Grotsky HW**, Rickert RR, Smith WD, Newsome JF. Familial juvenile polyposis coli. A clinical and pathologic study of a large kindred. *Gastroenterology* 1982; **82**: 494-501 [PMID: 7054044]
- 60 **van Hattem WA**, Langeveld D, de Leng WW, Morsink FH, van Diest PJ, Iacobuzio-Donahue CA, Giardiello FM, Offerhaus GJ, Brosens LA. Histologic variations in juvenile polyp phenotype correlate with genetic defect underlying juvenile polyposis. *Am J Surg Pathol* 2011; **35**: 530-536 [PMID: 21412070 DOI: 10.1097/PAS.0b013e318211cae1]
- 61 **Brosens LA**, Langeveld D, van Hattem WA, Giardiello FM, Offerhaus GJ. Juvenile polyposis syndrome. *World J Gastroenterol* 2011; **17**: 4839-4844 [PMID: 22171123 DOI: 10.3748/wjg.v17.i44.4839]
- 62 **Delnatte C**, Sanlaville D, Mougenot JF, Vermeesch JR, Houdayer C, Blois MC, Genevieve D, Goulet O, Fryns JP, Jaubert F, Vekemans M, Lyonnet S, Romana S, Eng C, Stoppa-Lyonnet D. Contiguous gene deletion within chromosome arm 10q is associated with juvenile polyposis of infancy, reflecting cooperation between the BMPRIA and PTEN tumor-suppressor genes. *Am J Hum Genet* 2006; **78**: 1066-1074 [PMID: 16685657 DOI: 10.1086/504301]
- 63 **Brosens LA**, van Hattem WA, Jansen M, de Leng WW, Giardiello FM, Offerhaus GJ. Gastrointestinal polyposis syndromes. *Curr Mol Med* 2007; **7**: 29-46 [PMID: 17311531 DOI: 10.2174/156652407779940404]
- 64 **Sachatello CR**, Griffen WO Jr. Hereditary polypoid diseases of the gastrointestinal tract: a working classification. *Am J Surg* 1975; **129**: 198-203 [PMID: 1091175 DOI: 10.1016/0002-9610(75)90298-6]
- 65 **Gallione CJ**, Repetto GM, Legius E, Rustgi AK, Schelley SL, Tejpar S, Mitchell G, Drouin E, Westermann CJ, Marchuk DA. A combined syndrome of juvenile polyposis and hereditary haemorrhagic telangiectasia associated with mutations in MADH4 (SMAD4). *Lancet* 2004; **363**: 852-859 [PMID: 15031030 DOI: 10.1016/S0140-6736(04)15732-2]
- 66 **Desai DC**, Murday V, Phillips RK, Neale KF, Milla P, Hodgson SV. A survey of phenotypic features in juvenile polyposis. *J Med Genet* 1998; **35**: 476-481 [PMID: 9643289 DOI: 10.1136/jmg.35.6.476]
- 67 **Baert AL**, Casteels-Van Daele M, Broeckx J, Wijndaele L, Wilms G, Eggermont E. Generalized juvenile polyposis with pulmonary arteriovenous malformations and hypertrophic osteoarthropathy. *AJR Am J Roentgenol* 1983; **141**: 661-662 [PMID: 6604412 DOI: 10.2214/ajr.141.4.661]
- 68 **Williams JC**, Hamilton JK, Shiller M, Fischer L, Deprisco G, Boland CR. Combined juvenile polyposis and hereditary hemorrhagic telangiectasia. *Proc (Bayl Univ Med Cent)* 2012; **25**: 360-364 [PMID: 23077388 DOI: 10.1080/08998280.2012.11928877]
- 69 **Schwenter F**, Faughnan ME, Gradinger AB, Berk T, Gryfe R, Pollett A, Cohen Z, Gallinger S, Durno C. Juvenile polyposis, hereditary hemorrhagic telangiectasia, and early onset colorectal cancer in patients with SMAD4 mutation. *J Gastroenterol* 2012; **47**: 795-804 [PMID: 22331366 DOI: 10.1007/s00535-012-0545-8]
- 70 **Haramis AP**, Begthel H, van den Born M, van Es J, Jonkheer S, Offerhaus GJ, Clevers H. De novo crypt formation and juvenile polyposis on BMP inhibition in mouse intestine. *Science* 2004; **303**: 1684-1686 [PMID: 15017003 DOI: 10.1126/science.1093587]
- 71 **Woodford-Richens K**, Williamson J, Bevan S, Young J, Leggett B, Frayling I, Thway Y, Hodgson S, Kim JC, Iwama T, Novelli M, Sheer D, Poulson R, Wright N, Houlston R, Tomlinson I. Allelic loss at SMAD4 in polyps from juvenile polyposis patients and use of fluorescence in situ hybridization to demonstrate clonal origin of the epithelium. *Cancer Res* 2000; **60**: 2477-2482 [PMID: 10811127]
- 72 **Schutte M**, Hruban RH, Hedrick L, Cho KR, Nadasdy GM, Weinstein CL, Bova GS, Isaacs WB, Cairns P, Nawroz H, Sidransky D, Casero RA Jr, Meltzer PS, Hahn SA, Kern SE. DPC4 gene in various tumor types. *Cancer Res* 1996; **56**: 2527-2530 [PMID: 8653691]

- 73 **Brosens LA**, van Hattem A, Hyland LM, Iacobuzio-Donahue C, Romans KE, Axilbund J, Cruz-Correa M, Tersmette AC, Offerhaus GJ, Giardiello FM. Risk of colorectal cancer in juvenile polyposis. *Gut* 2007; **56**: 965-967 [PMID: [17303595](#) DOI: [10.1136/gut.2006.116913](#)]
- 74 **Jass JR**, Williams CB, Bussey HJ, Morson BC. Juvenile polyposis--a precancerous condition. *Histopathology* 1988; **13**: 619-630 [PMID: [2853131](#) DOI: [10.1111/j.1365-2559.1988.tb02093.x](#)]
- 75 **Aytac E**, Sulu B, Heald B, O'Malley M, LaGuardia L, Remzi FH, Kalady MF, Burke CA, Church JM. Genotype-defined cancer risk in juvenile polyposis syndrome. *Br J Surg* 2015; **102**: 114-118 [PMID: [25389115](#) DOI: [10.1002/bjs.9693](#)]
- 76 **Gonzalez RS**, Adsay V, Graham RP, Shroff SG, Feely MM, Drage MG, Lewin DN, Swanson EA, Yantiss RK, Bağci P, Krasinskas AM. Massive gastric juvenile-type polyposis: a clinicopathological analysis of 22 cases. *Histopathology* 2017; **70**: 918-928 [PMID: [27991685](#) DOI: [10.1111/his.13149](#)]
- 77 **Larsen Haidle J**, MacFarland SP, Howe JR. Juvenile Polyposis Syndrome. 2003 May 13. In: GeneReviews® [Internet]. Seattle (WA): University of Washington, Seattle; 1993– [PMID: [20301642](#)]
- 78 **Chow E**, Macrae F. A review of juvenile polyposis syndrome. *J Gastroenterol Hepatol* 2005; **20**: 1634-1640 [PMID: [16246179](#) DOI: [10.1111/j.1440-1746.2005.03865.x](#)]
- 79 **van Hattem WA**, Brosens LA, Marks SY, Milne AN, van Eeden S, Iacobuzio-Donahue CA, Ristimäki A, Giardiello FM, Offerhaus GJ. Increased cyclooxygenase-2 expression in juvenile polyposis syndrome. *Clin Gastroenterol Hepatol* 2009; **7**: 93-97 [PMID: [19124115](#) DOI: [10.1016/j.cgh.2008.07.030](#)]
- 80 **Chen HY**, Jin XW, Li BR, Zhu M, Li J, Mao GP, Zhang YF, Ning SB. Cancer risk in patients with Peutz-Jeghers syndrome: A retrospective cohort study of 336 cases. *Tumour Biol* 2017; **39**: 1010428317705131 [PMID: [28653895](#) DOI: [10.1177/1010428317705131](#)]
- 81 **Hearle N**, Schumacher V, Menko FH, Olschwang S, Boardman LA, Gille JJ, Keller JJ, Westerman AM, Scott RJ, Lim W, Trimbath JD, Giardiello FM, Gruber SB, Offerhaus GJ, de Rooij FW, Wilson JH, Hansmann A, Möslin G, Royer-Pokora B, Vogel T, Phillips RK, Spigelman AD, Houlston RS. Frequency and spectrum of cancers in the Peutz-Jeghers syndrome. *Clin Cancer Res* 2006; **12**: 3209-3215 [PMID: [16707622](#) DOI: [10.1158/1078-0432.CCR-06-0083](#)]
- 82 **Ishida H**, Tajima Y, Gonda T, Kumamoto K, Ishibashi K, Iwama T. Update on our investigation of malignant tumors associated with Peutz-Jeghers syndrome in Japan. *Surg Today* 2016; **46**: 1231-1242 [PMID: [26746637](#) DOI: [10.1007/s00595-015-1296-y](#)]
- 83 **Korsse SE**, Harinck F, van Lier MG, Biermann K, Offerhaus GJ, Krak N, Looman CW, van Veelen W, Kuipers EJ, Wagner A, Dekker E, Mathus-Vliegen EM, Fockens P, van Leerdam ME, Bruno MJ. Pancreatic cancer risk in Peutz-Jeghers syndrome patients: a large cohort study and implications for surveillance. *J Med Genet* 2013; **50**: 59-64 [PMID: [23240097](#) DOI: [10.1136/jmedgenet-2012-101277](#)]
- 84 **Mehenni H**, Resta N, Park JG, Miyaki M, Guanti G, Costanza MC. Cancer risks in LKB1 germline mutation carriers. *Gut* 2006; **55**: 984-990 [PMID: [16407375](#) DOI: [10.1136/gut.2005.082990](#)]
- 85 **Giardiello FM**, Brensinger JD, Tersmette AC, Goodman SN, Petersen GM, Booker SV, Cruz-Correa M, Offerhaus JA. Very high risk of cancer in familial Peutz-Jeghers syndrome. *Gastroenterology* 2000; **119**: 1447-1453 [PMID: [11113065](#) DOI: [10.1053/gast.2000.20228](#)]
- 86 **Cai HJ**, Wang H, Cao N, Wang W, Sun XX, Huang B. Peutz-Jeghers syndrome with mesenteric fibromatosis: A case report and review of literature. *World J Clin Cases* 2020; **8**: 577-586 [PMID: [32110669](#) DOI: [10.12998/wjcc.v8.i3.577](#)]
- 87 **Tan MH**, Mester JL, Ngeow J, Rybicki LA, Orloff MS, Eng C. Lifetime cancer risks in individuals with germline PTEN mutations. *Clin Cancer Res* 2012; **18**: 400-407 [PMID: [2252256](#) DOI: [10.1158/1078-0432.CCR-11-2283](#)]
- 88 **Fackenthal JD**, Marsh DJ, Richardson AL, Cummings SA, Eng C, Robinson BG, Olopade OI. Male breast cancer in Cowden syndrome patients with germline PTEN mutations. *J Med Genet* 2001; **38**: 159-164 [PMID: [11238682](#) DOI: [10.1136/jmg.38.3.159](#)]
- 89 **Harach HR**, Soubeyran I, Brown A, Bonneau D, Longy M. Thyroid pathologic findings in patients with Cowden disease. *Ann Diagn Pathol* 1999; **3**: 331-340 [PMID: [10594284](#) DOI: [10.1016/s1092-9134\(99\)80011-2](#)]
- 90 **Ngeow J**, Mester J, Rybicki LA, Ni Y, Milas M, Eng C. Incidence and clinical characteristics of thyroid cancer in prospective series of individuals with Cowden and Cowden-like syndrome characterized by germline PTEN, SDH, or KLLN alterations. *J Clin Endocrinol Metab* 2011; **96**: E2063-E2071 [PMID: [21956414](#) DOI: [10.1210/jc.2011-1616](#)]
- 91 **Heald B**, Mester J, Rybicki L, Orloff MS, Burke CA, Eng C. Frequent gastrointestinal polyps and colorectal adenocarcinomas in a prospective series of PTEN mutation carriers. *Gastroenterology* 2010; **139**: 1927-1933 [PMID: [20600018](#) DOI: [10.1053/j.gastro.2010.06.061](#)]
- 92 **NCCN 2**. Genetic/Familial High-Risk Assessment: Breast, Ovarian, and Pancreatic. 2022. [cited 10 October 2022]. Available from: <https://gs.amegroups.com/article/view/12766/13741>
- 93 **Howe JR**, Mitros FA, Summers RW. The risk of gastrointestinal carcinoma in familial juvenile polyposis. *Ann Surg Oncol* 1998; **5**: 751-756 [PMID: [9869523](#) DOI: [10.1007/BF02303487](#)]
- 94 **Dove-Edwin I**, Sasieni P, Adams J, Thomas HJ. Prevention of colorectal cancer by colonoscopic surveillance in individuals with a family history of colorectal cancer: 16 year, prospective, follow-up study. *BMJ* 2005; **331**: 1047 [PMID: [16243849](#) DOI: [10.1136/bmj.38606.794560.EB](#)]
- 95 **Heald B**, Rigelsky C, Moran R, LaGuardia L, O'Malley M, Burke CA, Zahka K. Prevalence of thoracic aortopathy in patients with juvenile Polyposis Syndrome-Hereditary Hemorrhagic Telangiectasia due to SMAD4. *Am J Med Genet A* 2015; **167A**: 1758-1762 [PMID: [25931195](#) DOI: [10.1002/ajmg.a.37093](#)]
- 96 **Teekakirikul P**, Milewicz DM, Miller DT, Lacro RV, Regalado ES, Rosales AM, Ryan DP, Toler TL, Lin AE. Thoracic aortic disease in two patients with juvenile polyposis syndrome and SMAD4 mutations. *Am J Med Genet A* 2013; **161A**: 185-191 [PMID: [23239472](#) DOI: [10.1002/ajmg.a.35659](#)]



Published by **Baishideng Publishing Group Inc**  
7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

**Telephone:** +1-925-3991568

**E-mail:** [bpgoffice@wjgnet.com](mailto:bpgoffice@wjgnet.com)

**Help Desk:** <https://www.f6publishing.com/helpdesk>

<https://www.wjgnet.com>

